Johnson & Johnson Stock News

Market volatility can be unsettling for any investor.

U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, with both citing increased threats after a UnitedHealth insurance executive was murdered outside the company's investor meeting in December, regulatory filings show.

DALLAS--(BUSINESS WIRE)--Leading plaintiff trial firm Dean Omar Branham Shirley, LLP is pleased to announce the selection of partners Jessica Dean, Amin Omar, Trey Branham, Lisa Shirley, Ben Braly and attorney Mark Linder to the list of Lawdragon's 500 Leading Plaintiff Consumer Lawyers for 2025. The annual listing describes this year's honorees as “coast-to-coast champions who dedicate their l...

The advent of artificial intelligence (AI) and machine learning has, in many ways, revolutionized the financial markets.

Investors were in growth mode in the last two years as the stock market delivered blockbuster returns.

Topline results also show investigational targeted oral peptide icotrokinra achieved clinical remission rates up to 30.2% at Week 12 and a favorable safety profile in Phase 2b ANTHEM-UC study Clinical response and remission rates continued to improve through Week 28, building on strong data recently reported for the plaque psoriasis Phase 3 program Icotrokinra demonstrates potential to offer th...

Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD Topline results from Phase 3 ICONIC-ADVANCE 1&2 studies show icotrokinra achieved c...

Johnson & Johnson and Pfizer occupy leading positions in the healthcare sector. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the comparator. In this article you will find out who is more promising for long-term investors.